title: Maternal obesity and risk of neural tube defects.
abstract: OBJECTIVE
  One of my patients is taking olanzapine for schizophrenia. She has gained a lot of weight, which, I understand, often happens with some of the new atypical antipsychotics. Due to her weight gain, she failed to notice she had become pregnant. Is she at risk?
  
  
  CONCLUSIONS
  Experience with olanzapine is relatively slight, but available prospective data do not show increased teratogenic risk. Adiposity, on the other hand, is associated with increased risk of neural tube defects. Only some of this risk can be reduced by folate supplementation.
authors.affiliation: Hospital for Sick Children, Toronto, Ont.
authors.forename: G
authors.initials: G
authors.lastname: Koren
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects; D001569:Benzodiazepines; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D009436:Neural Tube Defects / Q000453:epidemiology* / Q000517:prevention & control; D009765:Obesity / Q000139:chemically induced; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives; D011247:Pregnancy; D011248:Pregnancy Complications; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D005492:Folic Acid; D000077152:Olanzapine